Interdisciplinary assessment and diagnostic algorithm: The role of the diabetologist

Lalić, Nebojša

doi:10.1016/j.diabres.2021.108850

Cited by 2 publications

(4 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…advanced glycation end product (AGE) deposition, lipid toxicity, and microvascular rarefication ( Low Wang et al., 2016 ). These adverse effects of T2D were more pronounced in HFpEF ( Lalic, 2021 ; Tadic et al., 2021 ). T2D with HFpEF is featured by LV diastolic dysfunction (LVDD) and decreased LV cavity with elevated LV filling pressure, as well as endothelial and coronary microvascular dysfunction ( Paulus and Dal Canto, 2018 ).…”

Section: Pathophysiology Of Hfpef In T2dmentioning

confidence: 94%

“…T2D plays an essential role in the onset of HFpEF ( Lalic, 2021 ; Tadic et al., 2021 ). Compared with non-diabetics, the incidence and mortality of CVD and HF are much higher in T2D patients ( Bullard et al., 2018 ; Xu et al., 2018 ).…”

Section: Epidemiology and Prognosis Of Hfpef In T2dmentioning

confidence: 99%

“…With concurrent T2D and HFpEF, endothelial dysfunction indecently disrupts ventricular–vascular uncoupling and contributes to pathological changes in T2D with HFpEF ( Lalic, 2021 ; Tadic et al., 2021 ). Systolic dysfunction often leads to subsequent impairment of LV diastolic function.…”

Section: Pathophysiology Of Hfpef In T2dmentioning

confidence: 99%

“…Other than T2D, various complications, including obesity, hypertension, dyslipidemia, renal disease, and atrial fibrillation, also closely correlate with HFpEF ( Taqueti et al., 2018 ). Given the high prevalence and poor prognosis of HFpEF, intensive therapy is pertinent for the management of cardiovascular anomalies in patients with T2D ( Lalic, 2021 ; Tadic et al., 2021 ). Nonetheless, current treatment modality remains dismal largely due to the poorly defined pathophysiology of HFpEF in T2D.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics

Abudureyimu

Luo

Wang

et al. 2022

Journal of Molecular Cell Biology

View full text Add to dashboard Cite

Type 2 diabetes mellitus (T2D) is a devastating metabolic abnormality featured by insulin resistance, hyperglycemia, and hyperlipidemia. T2D provokes unique metabolic changes and compromises cardiovascular geometry and function. Meanwhile, T2D increases the overall risk for heart failure (HF) and acts independent of classical risk factors including coronary artery disease, hypertension, and valvular heart diseases. The incidence of HF is extremely high in patients with T2D and is manifested as heart failure with preserved, reduced, and midrange ejection fraction (HFpEF, HFrEF, and HFmrEF, respectively), all of which significantly worsen the prognosis for T2D. HFpEF is seen in approximately half of HF cases and is defined as a heterogenous syndrome with discrete phenotypes, in particularly in close association with metabolic syndrome. Nonetheless, management of HFpEF in T2D remains unclear, largely due to the poorly defined pathophysiology behind HFpEF. Here, in this review, we will summarize findings from multiple preclinical and clinical studies as well as recent clinical trials, mainly focusing on the pathophysiology, potential mechanisms, and therapies of HFpEF in T2D.

show abstract

Section: Pathophysiology Of Hfpef In T2dmentioning

confidence: 94%